3 Dividend Aristocrats: Buy, Sell or Hold?

Three Dividend Aristocrats, three different setups. PepsiCo (NASDAQ:PEP | PEP Price Prediction) trades at $146.12 and screens as the most attractive of the three. Coca-Cola (NYSE:KO) at $80.28 looks fully valued. Procter & Gamble (NYSE:PG) at $152.49 faces a tougher near-term setup.

With the S&P 500 up 10.03% year to date, each name is pricing in a different story about consumer staples. Treat analyst targets below as one data point among many.

PepsiCo: A Beaten-Down Aristocrat With Room to Run

At $146.12, PepsiCo looks attractively priced. Pepsi trades at a forward P/E of 17, well below Coke’s 25, after lagging the market at +3.79% YTD.

Q1 FY26 core EPS of $1.61 beat the $1.5442 consensus, revenue of $19.44 billion grew 8.5% YoY, and international carried the quarter: EMEA core operating profit +29%, Asia Pacific Foods +35%, LatAm Foods +16%. North America volume finally turned positive.

The bear case is real. Rockstar impairments dragged FY25 operating income to -19.57%, tariffs and commodities remain margin overhangs, and PFNA snacks only just stabilized. Even so, management reaffirmed FY26 organic revenue growth of 2-4% and core EPS growth of 4-6%, and lifted the dividend 4% to $5.92 annualized, the 54th straight raise.

The $168.50 analyst target implies roughly 15% upside, with 8 of 23 analysts at Buy or Strong Buy. The setup pays you to wait for the international flywheel to compound.

Coca-Cola: Priced for Perfection

At $80.28, Coca-Cola is priced for perfection. The business is executing. Q1 FY26 EPS of $0.86 beat by 5.87%, organic revenue grew 10%, unit case volume rose 3%, Zero Sugar volume jumped 13%, and management raised 2026 comparable EPS growth guidance to 8% to 9%. Operating margin expanded to 35%.

The price is the problem. KO trades at a trailing P/E of 26 and forward 25, and the $85.97 analyst target implies only about 7% upside. Shares are already up 16.38% YTD, well ahead of the S&P’s 10.03%.

A $960 million BODYARMOR impairment, a roughly 4% revenue headwind from the CCBA divestiture in H2 2026, and ongoing IRS tax litigation cap the move. Of 24 analysts, 19 rate it Buy or Strong Buy, but at this entry the risk-reward is balanced. The risk-reward improves on a pullback.

Procter & Gamble: Quality, Wrong Entry

At $152.49, Procter & Gamble offers quality at a full price. Fiscal Q3 2026 core EPS of $1.59 beat by 2.24%, sales of $21.235 billion beat by 3.50%, Beauty grew 7% organic, and the 70th consecutive dividend increase keeps Aristocrat status intact. The $163.43 analyst target points to about 7% upside.

The catch: management now expects FY26 to land toward the lower end of its $6.83-$7.09 core EPS range, meaning earnings may be roughly flat against FY25’s $6.83. A $400 million after-tax tariff cost, $150 million commodity headwind, and 100 basis points of core gross margin compression are concrete.

Q2 organic sales were flat with Baby, Feminine & Family Care down 4%. PG is up 7.94% YTD, trailing the index, with 14 of 24 analysts at Buy or better, 10 at Hold, and a forward P/E of 21. The setup rewards patience. Watch volume trends and tariff guidance into fiscal Q4 before stepping up.